EMEND® (aprepitant) 125/80mg
Product Overview
| Generic Name | EMEND® (aprepitant) 125/80mg |
| Brand Name(s) | Emend® |
| Category | Antineoplastic / Cancer |
| Form | 1 × 125 mg + 2 × 80 mg; 3 capsules (oral) Tri-Pak |
| Strength | 125/80mg |
| Therapeutic Class | Neurokinin-1 (NK1) receptor antagonist antiemetic |
| ATC Code | A04AD12 |
Manufacturing & Regulatory
| Manufacturer | Originator/MAH: Merck / Merck Sharp & Dohme |
| GMP Compliance | cGMP / EU-GMP |
| COFEPRIS | 010.000.4442.00 |
| Free Sale Certificate | Available per batch upon request |
Logistics & Export
| MOQ | 5 |
| Shelf Life | 24 Months |
| Storage | controlled room temperature |
| Incoterms | Ex-Works, 30049049 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes — batch-specific COA should be provided |
| CTD Summary (PDF) | Public FDA/EMA label/SmPC available; full CTD is not public |
Special Notes
EMEND is indicated as an NK1 receptor antagonist used in combination regimens to prevent nausea and vomiting associated with highly or moderately emetogenic chemotherapy and for prevention of postoperative nausea and vomiting in appropriate patients / Caja con 1 capsula de 125mg y 2 capsulas de 80mg via oral